1. Home
  2. MPLT vs CLVT Comparison

MPLT vs CLVT Comparison

Compare MPLT & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

HOLD

Current Price

$36.90

Market Cap

1.3B

Sector

Health Care

ML Signal

HOLD

Logo Clarivate Plc

CLVT

Clarivate Plc

HOLD

Current Price

$2.06

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
MPLT
CLVT
Founded
2018
2016
Country
United States
United Kingdom
Employees
133
12000
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.5B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MPLT
CLVT
Price
$36.90
$2.06
Analyst Decision
Strong Buy
Hold
Analyst Count
7
7
Target Price
$32.67
$3.22
AVG Volume (30 Days)
563.2K
9.1M
Earning Date
05-28-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$2.12
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$1.66
52 Week High
$40.43
$4.77

Technical Indicators

Market Signals
Indicator
MPLT
CLVT
Relative Strength Index (RSI) 54.74 42.54
Support Level $26.20 $1.90
Resistance Level $40.43 $2.65
Average True Range (ATR) 2.75 0.18
MACD -0.46 -0.03
Stochastic Oscillator 35.78 31.29

Price Performance

Historical Comparison
MPLT
CLVT

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About CLVT Clarivate Plc

Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.

Share on Social Networks: